Clover Health Investments | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 496.65 B

LB filings
2025.11.07 13:08
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 496.65 B, beating the estimate of USD 471.08 M.

EPS: As of FY2025 Q3, the actual value is USD -0.05.

EBIT: As of FY2025 Q3, the actual value is USD -29.65 B, missing the estimate of USD -18.33 M.

Insurance Segment

Premiums Earned, Net

  • For the three months ended September 30, 2025, premiums earned, net were $479.1 million, a 48.5% increase from $322.6 million for the same period in 2024.
  • For the nine months ended September 30, 2025, premiums earned, net were $1,405.9 million, a 38.6% increase from $1,014.2 million for the same period in 2024.

Net Medical Claims Incurred

  • For the three months ended September 30, 2025, net medical claims incurred were $423.5 million, a 69.5% increase from $249.8 million for the same period in 2024.
  • For the nine months ended September 30, 2025, net medical claims incurred were $1,154.9 million, a 51.3% increase from $763.3 million for the same period in 2024.

Salaries and Benefits

  • For the three months ended September 30, 2025, salaries and benefits were $48.2 million, a 12.4% decrease from $55.0 million for the same period in 2024.
  • For the nine months ended September 30, 2025, salaries and benefits were $168.5 million, a 0.7% decrease from $169.7 million for the same period in 2024.

General and Administrative Expenses

  • For the three months ended September 30, 2025, general and administrative expenses were $49.0 million, a 39.1% increase from $35.2 million for the same period in 2024.
  • For the nine months ended September 30, 2025, general and administrative expenses were $148.1 million, a 19.3% increase from $124.2 million for the same period in 2024.

Net Loss from Continuing Operations

  • For the three months ended September 30, 2025, the net loss from continuing operations was $24.4 million, compared to a net loss of $8.8 million for the same period in 2024.
  • For the nine months ended September 30, 2025, the net loss from continuing operations was $36.2 million, compared to a net loss of $24.8 million for the same period in 2024.

Cash Flow

Operating Cash Flow

  • Net cash provided by operating activities from continuing operations was $1.2 million for the nine months ended September 30, 2025, compared to $129.5 million for the same period in 2024.

Investing Cash Flow

  • Net cash provided by investing activities was $39.1 million for the nine months ended September 30, 2025, compared to $2.0 million for the same period in 2024.

Financing Cash Flow

  • Net cash used in financing activities was $44.8 million for the nine months ended September 30, 2025, compared to $11.2 million for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

  • Clover Health aims to empower physicians with technology to identify, manage, and treat chronic diseases earlier, focusing on improving care for Medicare beneficiaries through its Clover Assistant platform.

Non-Core Business

  • The company launched Counterpart Health, Inc., a SaaS and Tech Enabled Services Solution, to extend the benefits of its technology to a wider audience, aiming for growth and high-margin business opportunities.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.